CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 April to 30 June 2019.
5 min read
SCENESSE® registration dossier submitted in Australia
CLINUVEL initiates the registration process under priority review for its new pharmaceutical...Read More
1 min read
Notice of Change of Interests of Substantial Holder
Form 604 – Notice of change of interests of substantial holder...Read More